Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat blindness diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many”. And our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.
I might've marked this up a few weeks ago. However, here is an updated outlook after hearing some positive news from its camp that was released today.
What do you think?
Like, Follow, Agree, Disagree!
Details in photo!
Strike price $12.12
I might've marked this up a few weeks ago. However, here is an updated outlook after hearing some positive news from its camp that was released today.
What do you think?
Like, Follow, Agree, Disagree!
Details in photo!
Strike price $12.12
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.